Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock Holdings Increased by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale grew its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 26.0% during the first quarter, HoldingsChannel reports. The institutional investor owned 115,308 shares of the specialty pharmaceutical company’s stock after buying an additional 23,768 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Jazz Pharmaceuticals were worth $13,938,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in JAZZ. Vanguard Group Inc. increased its holdings in shares of Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after acquiring an additional 84,941 shares during the period. LSV Asset Management increased its stake in shares of Jazz Pharmaceuticals by 1.6% in the first quarter. LSV Asset Management now owns 2,380,858 shares of the specialty pharmaceutical company’s stock valued at $286,703,000 after purchasing an additional 37,631 shares during the period. Polaris Capital Management LLC raised its holdings in shares of Jazz Pharmaceuticals by 13.0% during the first quarter. Polaris Capital Management LLC now owns 1,432,660 shares of the specialty pharmaceutical company’s stock valued at $172,521,000 after buying an additional 165,200 shares during the last quarter. Capital World Investors acquired a new position in shares of Jazz Pharmaceuticals during the first quarter worth approximately $171,943,000. Finally, Baupost Group LLC MA grew its holdings in Jazz Pharmaceuticals by 23.7% in the 4th quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock worth $102,545,000 after buying an additional 160,000 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 1.0 %

NASDAQ JAZZ traded down $1.12 during trading on Friday, reaching $113.26. 716,259 shares of the company’s stock were exchanged, compared to its average volume of 655,591. The firm has a market capitalization of $7.14 billion, a PE ratio of 23.35, a P/E/G ratio of 1.76 and a beta of 0.58. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $146.70. The company has a current ratio of 2.37, a quick ratio of 1.90 and a debt-to-equity ratio of 1.36. The company’s fifty day simple moving average is $107.82 and its 200-day simple moving average is $114.11.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing the consensus estimate of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The company had revenue of $901.98 million during the quarter, compared to analyst estimates of $938.99 million. Sell-side analysts predict that Jazz Pharmaceuticals plc will post 15.31 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on JAZZ shares. Robert W. Baird cut their target price on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research note on Thursday. HC Wainwright reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday. The Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They set a “buy” rating and a $169.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday. Finally, Royal Bank of Canada lowered their price objective on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a research note on Thursday. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $175.20.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.